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Summary The use of continuous prognostic variables is clinically impractical, and arbitrarily chosen cut-off
points can result in a loss of prognostic information. Here we report findings from a study of primary breast
cancer, showing how the prognostic value of the fraction of cells in the S-phase of the cell cycle (SPF), as
measured by flow cytometry, can be affected by the SPF cut-off level(s) adopted. It was possible to evaluate
the SPF in 566 (94%) of 603 consecutive cases where fresh frozen specimens were available in a tumour bank
at our department. Clinically, all patients were without distant spread at the time of diagnosis, and the median
duration of follow-up was 4 years. Using different survival end-points and x2 values for each cut-off level, two
optimal cut-off points, at the 7% and 12% levels, were consistently obtained for the SPF. Furthermore, both
disease-free survival and the relative risk of recurrence exhibited a non-linear relationship with SPF values; the
curves implied that the prognosis was better among patients with SPF values about 2-5% than in patients
with lower SPF values (parabolic shape), though the relationship with higher SPF values approached linearity.
The non-linearity of the curves is incompatible with the general use of the median SPF as a prognostic cut-off
value. An alternative procedure might be to use two cut-off levels, one to distinguish patients with the lowest
SPF values (i.e. within the parabolic survival curve) from those with higher values (i.e. with a survival curve
approaching linearity), the other to distinguish between patients with intermediate SPF values and those with
high values (i.e. within the almost linear part of the survival curve). The 7% and 12% obtained here would be
suitable for this purpose. We conclude that prognostic information can be gained by dividing the SPF into
three prognostic categories (<7.0%, 7.0-11.9% and > 12%), instead of using the median SPF level.
One of the primary concerns in clinical oncology is the
search for prognostic factors, enabling estimation of the
likelihood of individual patients developing recurrence or
dying in the first 5 years after diagnosis of malignant disease.
Variables which provide substantial prognostic information
can be useful guides in the choice of treatment or in the
prognostic stratification of patients included in clinical trials.
TNM staging, including information about tumour size, axil-
lary node status and presence or absence of distant metas-
tasis, is currently the only generally accepted prognostic
system in primary breast cancer.
Among the promising new prognostic factors in primary
breast cancer is proliferative activity in tumour cells, which
can be measured in a number of ways, the simplest and least
time-consuming of which is to measure the proportion of
cells synthesising DNA at a given time (McDivitt et al.,
1986). This can either be done with the thymidine labelling
index technique, or by measuring the DNA content of a large
number ofcells, usually by flow cytometry, and estimation of
the SPF (McDivitt et al., 1986). In both methods it has been
demonstrated with multivariate analysis that proliferative
activity is an independent prognostic factor in primary breast
cancer (Meyer et al., 1983; Tubiana et al., 1984; Silvestrini et
al., 1986; Klintenberg et al., 1986; Kallioniemi et al., 1988;
Clark et al., 1989; Courdi et al., 1989; Sigurdsson et al.,
1990).
The SPF is a continuous variable, and higher values are
usually obtained with flow cytometry than with thymidine
labelling; McDivitt et al. (1986) have demonstrated that the
values obtained with the two methods are comparable. In
general, it is impractical to use continuous variables for
prognostic purposes, but there is no general agreement as to
how the SPF should be categorised. At present, most inves-
tigators use the median value of the SPF as a cut-off level for
prognostic purposes.
The aim of the current study was to elicit optimal cut-off
levels for the SPF in primary breast cancer, as determined
with FCM.
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Patients and methods
In the health care region of southern Sweden hormone recep-
tor analyses are routinely performed on specimens from
patients with primary breast cancer, any residual tumour
specimens being stored in a tumour bank at the Oncology
Department at University Hospital in Lund.
The study included 603 consecutive cases where specimens
were available in the tumour bank, and which fulfilled the
following inclusion criteria: (1) tumour sample from primary
breast cancer (cancer in situ excluded); (2) diagnosed during
the period between September 1982 and January 1986; (3)
clinically without signs of distant metastasis at the time of
diagnosis; (4) sufficient tumour specimen to yield a DNA
histogram; and (5) tumour cells microscopically identified in
a cytopathologic investigation of all imprints used for mak-
ing cell suspensions for DNA analysis.
The median age of the patient population was 63 years
(range 26-97). Tumour size was taken from the pathological
report and usually determined on a unfixed specimen. A
median of ten axillary lymph nodes was investigated. The
distribution of cases by tumour size was as follows:
0-20mm, n=250 (41%); 21-50mm, n=317 (53%); and
> 51 mm, n = 36 (6%). Distribution by axillary lymph node
status was: node-negative, n = 303 (50%); node-positive,
n = 277 (46%); and no axillary staging performed, n = 23
(4%).
Laboratory methods
Tumour samples were taken from biopsies originally obtain-
ed for steroid receptor analysis. Fresh specimens from the
macroscopic mammary tumours were taken by the examining
pathologist, except in a few cases where it was done during
surgery. The specimens were stored frozen (- 70°C), and
later analysed (in a single laboratory) at the Oncology
Department in Lund. Flow cytometry as described in detail
elsewhere (Baldetorp et al., 1989) was performed on about
100-200 mg of tumour tissue thawed in 100-200,4 ofcitrate
buffer (sucrose 250 mM, trisodium citrate 40 mm and di-
methylsulphoxide 5%, pH 7.6) containing chicken (CRBC)
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and trout (TRBC) red blood cells, i.e. approximately 106
cells ml-' (Vindelov et al., 1983). To increase cell elution, the
tissue was mechanically disintegrated with two forceps, after
which 1-2 ml of nuclear isolation medium, containing pro-
pidium iodide (PI) for the staining of DNA, was added
(50tLg PI ml-', SIGMA P-5264; RNAse 0.1 mg ml-' and
SIGMA R5125; Nonidet P 40 0.6% (v/v) in isotonic phos-
phate buffered saline, GIBCO) (Lee et al., 1984; Thorn-
thwaite et al., 1980). The samples were filtered (140tsm) and
incubated in the dark for 10 min at room temperature, after
which they were kept at + 4°C until flow cytometry was
performed (within 60 min). The DNA content in individual
cell nuclei was anlaysed in an Ortho cytofluorograph 50-H
system. At least 15,000 nuclei were analysed per sample
(according to the peak-area detector), doublet data being
excluded (Ortho mod 2140). The mean value for the co-
efficients of variation (CV) was 2.5 ± 1.2 (s.d.) for the inter-
nal standard (TRBC), and 3.2 ± 1.0 (s.d.) for the 2C region
Go/G, peak. The modal DNA values of the internal stan-
dards (CRBC and TRBC) were used for zero point adjust-
ment of the DNA histogram (Vindel6v et al., 1983). The
adjusted mean values of the Go/G, peaks were then used for
the calculation of DNA indices in relation to one of the
internal standards (TRBC). Tumour ploidy status was
defined in accordance with the Nomenclature Convention for
DNA Cytometry (Hiddeman et al., 1984), one stem cell
population being diploid, and two or more stem cell popula-
tions to be non-diploid. Samples with a near-diploid or a
tetraploid cell population were consequently classified as
non-diploid. A peak comprising of approximately 5% or
more of the total number of events in the histogram was
regarded as a Go/G, peak if a corresponding G2 area was
detected. The fraction of measured events between the Go/GI
and G2 area was used to measure proliferative activity, i.e.
the fraction of cells corresponding to the area representing
the S-phase compartment of the cell cycle (SPF) assessed
with a planimetric method (Baisch et al., 1975). In cases of
bimodality in the 2C region and if the DNA index for the
non-diploid cell populations was below approximately 1.3 a
combined SPF value was calculated. The SPF was calculated
exclusively in the non-diploid stemline, when the DNA index
exceeded 1.3 and if the corresponding G2 peaks were distinct-
ly separated. The SPF in the most prominent non-diploid
stemline was calculated in cases where there were two or
more non-diploid peaks. No correction was made for back-
ground debris, but SPF was not calculated when background
debris predominated in the SPF region(s) of the histogram.
SPF was not calculated if the corresponding G2 peak in the
histogram could not be identified nor when the non-diploid
stemline was small (Go/G,< 10% of the total number of
observations).
Statistical methods
Survival estimations were done in accord with the Kaplan
and Meier method (1958). The cut-off levels for the SPF were
tested in 1% steps from the 4% level to the 14% level.
Survival estimations for patients below and above a chosen
cut-off level were compared by means of the log rank test
(Breslow, 1972) as previously used for the same purpose by
others (Courdi et al., 1988). Survival was analysed according
to four different categories: overall survival, breast cancer
survival, disease-free survival and distant disease-free sur-
vival. This was first done in the whole series at different
durations of follow-up, and subsequently in various sub-
groups of patients. The proportional hazards regression
model (Cox, 1972) was used to find optimal cut-off levels for
the SPF, results being adjusted for age at diagnosis ( 50 vs
> 50 years), tumour size (<20 mm vs <20 mm), lymph
node status (node-positive vs node-negative) and ploidy
status (non-diploid vs diploid). This was done both for the
patient population as a whole, and for each ploidy category.
A further investigation was performed by dividing the
series by SPF value into 19 categories ofapproximately equal
size (Abel et al., 1984). The estimated survival rate in each
category was related to the log SPF midpoint by inverse-
variance-weighted regression analysis, validity being investi-
gated with the proportional hazards regression model and
results adjusted as noted above (see previous paragraph).
Results
Of the total of 603 DNA histograms, 215 (36%) were diploid
and 388 (64%) were non-diploid. The median SPF value was
7.5% for the whole series, and 4.3% and 11% for the diploid
and the non-diploid categories, respectively (Figure 1).
Optimal SPF cut-offlevels
Analysing disease-free survival for the whole series, optimal
cut-off values for SPF were obtained both at the 7.0% and
the 12% levels, very similar values being obtained for the
other survival categories. These values were confirmed in the
whole series at different durations of follow-up (one, two,
three and four years), and in the node-positive and the
non-diploid tumour categories though they were less clear-cut
in the node-negative and the diploid groups. These values
were also confirmed in steroid receptor negative tumours
(oestrogen/progesterone) though in steroid receptor positive
tumours only a single cut-off was obtained at the 7% level.
Multivariate analysis adjusted for other prognostic factors,
using disease-free survival as end-point, confirmed the exist-
ence of optimal cut-off values both at the 7% and 12% levels
(Figure 2), though, the higher cut-off level was less clear-cut
in the diploid group.
Survival analysis
Figure 3 shows the disease-free survival by using different
cut-off levels: (i) with the median-SPF as the cut-off value
(P<0.0001); (ii) with the patients divided into three groups
of approximately equal size (P<0.0001) - the three groups
differed significantly from each other, but the actual differ-
ence in disease-free survival was not large between the low
and intermediate SPF categories (P = 0.01); and (iii) with the
two optimal cut-off levels (P<0.0001). These three groups
differed significantly from each other and yielded a better
discrimination than by dividing into three groups of approxi-
mately equal size (low vs intermediate SPF; P= 0.002). The
number of cases in the three SPF categories were: SPF
<7.0%, n= 265 (48%); 7.0<SPF< 11.9%, n= 117 (21%);
and SPF 12.0%, n= 174 (31%).
The upper part of Figure 4 shows the absolute disease-free
survival at 3 years of follow-up for each of the 19 SPF
categories as well as estimated survival rates. When the rela-
tionship between the log SPF and survival was estimated the
residuals indicated that the survival curve had a non-linear
function (parabolic shape); and adding a squared log SPF
improved the fit significantly (P<0.0001).
The lower part of Figure 4 shows the relative risk of
recurrence for the SPF according to proportional hazards
analysis, and adjusting for age, tumour size, axillary lymph
node status and ploidy status. Again a non-linear pattern was
found and again adding a squared log SPF improved the fit
significantly (P<0.0001).
Another proportional hazards analysis indicated that the
non-linear relationship between survival and SPF values may
be restricted to patients with diploid tumours (P = 0.07).
Multivariate analysis including the three SPF categories
(i.e. <7.0%, 7.0-11.9%, and >12%), as well as ploidy
status, and adjusting for other prognostic factors, showed
SPF categories to have independent prognostic value and
that ploidy status contributed no additional prognostic in-
formation.
It was possible to evaluate the SPF in 566 (94%) of the
tumour samples and all but one of the excluded samples were
non-diploid tumours (n = 37), the survival in these cases was
comparable with the survival for the remaining 566 patients.788 H. SIGURDSSON et al.
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Figure 1 Frequency distributions of fraction of cells in the S-
phase (SPF) of diploid 0 and non-diploid tumours * (in per
cent). The median SPF for the whole series was 7.5%, being
higher (P<0.0001) in non-diploid cases (11%) than in diploid
ones (4.3%).
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Figure 2 x2 values in a multivariate analysis (adjusted for age,
tumour size, axillary lymph node status and ploidy status) to
obtain cut-off levels (4.0-14%) for the fraction of cells in the
S-phase (SPF). , all patients; ---, patients with diploid
tumours; -----, patients with non-diploid tumours.
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Figure 3 Disease-free survival curves for three different ways of separating patients according to SPF values: (1) according to the
median SPF, (2) by SPF values to obtain three categories of approximately equal size and (3) using the three defined optimal
categories. The number of patients at risk at time 0, 2 and 4 years is shown for each category.
Discussion
That two optimal cut-off levels existed for the fraction of
cells in the S-phase (SPF) was a consistent finding when
using x2 values from survival estimates for each cut-off level.
These results were based on univariate analysis of data both
for the whole series and for various subgroups, as well as on
multivariate analysis where results were adjusted for other
prognostic factors (Figure 2). On the basis of these results,
we recommend a separation of the SPF values into three
prognostic groups, which in the present study were the fol-
lowing; <7.0%, 7.0-11.9% and > 12.0%. This principle
would seem to provide better prognostic information than
the median SPF level for the whole series.
Meyer and Province (1988) have used three groups of
approximately equal size to show the prognostic value of
SPF (thymidine labelling index). In the present investigation
this approach (using the three categories, <5.0%, 5.0-
11.9%, and > 12.0%) gave a better discrimination between
patients than using the median SPF value as a single cut-off
value (Figure 3), but not as good as that obtained by using
the two optimal cut-off values found here (giving the three
categories, <7.0%, 7.0-11.9%, and > 12.0%) (Figure 3).
The chief objection to using x2 values to elicit optimal
prognostic cut-off levels is that they are sensitive to the
number of cases or events in the groups being compared
(Abel et al., 1984). In an attempt to minimise such bias, we
tried using relative survival estimates after dividing the
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Figure 4 The series was divided by SPF values into 19 groups of
approximately equal size. The upper curves show the absolute
(straight line) and estimated (dotted line) disease-free survival at 3
years of follow-up for the 19 SPF groups (logarithmic scale). The
lower curve shows the relative risk of recurrence, adjusted for
other prognostic factors (i.e. age, tumour size, axillary lymph
node status and ploidy status (proportional hazards analysis).
patients by SPF values into groups of approximately equal
size (Abel et al., 1984). The survival curve was found to be
non-linear (parabolic shape), with survival rates increasing
with increasing SPF values in the group with low SPF values.
However, having peaked at about 3%, the survival rate then
decreased with increase SPF values (Figure 4). Multivariate
analysis of the relative risk of recurrence for different SPF
values (adjusted for other prognostic factors) also yielded a
non-linear curve, a striking mirror image of that for relative
survival (Figure 4). The non-linear pattern suggests that, for
optimal discrimination, the shape of the relationship between
survival and SPF should be taken into account, when defin-
ing prognostic cut-off points. Moreover, if one optimal cut-
off value is used, it should presumably be above the median
SPF value, as in fact has been the case in previous studies
where comparable methods were used to elicit optimal cut-off
levels (Courdi et al., 1988; Clark et al., 1989). In our opinion,
the parabolic shape of the survival curve is also an argument
against dividing the material into three equally sized SPF
categories, as there is better discrimination between survival
curves when two optimised cut-off values are used (Figure 3).
The clinical prognostic factors in breast cancer such as
axillary nodal status and tumour size are continuous vari-
ables. Fisher et al. (1983) have demonstrated that the prog-
nostic information of axillary lymph-node status can be
optimised by separating patients into three or more prognos-
tic groups. Had the median number of positive axillary
lymph nodes been recommended instead of further categoris-
ing the node positive group, there is a risk that this would
have resulted in a loss of prognostic information.
Although it is biologically plausible that tumours with high
SPF values will relapse earlier than tumours with low ones, it
is not biologically reasonable to expect an arbitrarily chosen
cut-off level such as the median value to provide optimal
prognostic information.
Meyer and Province (1988) and Tubiana et al. (1984),
measuring the SPF (thymidine labelling index), have used
two cut-off levels, although the values were arbitrarily
chosen. Courdi et al. (1988), also measuring the SPF with
thymidine labelling, used the log rank test to optimise the
cut-off level(s). Their conclusion was that a single cut-off
level should be used, and that the median SPF would serve
the purpose because the optimal cut-off level (2.4%) was
located near the median SPF level (2.1%). Nonetheless,
Courdi et al. (1988), also obtained two optimal cut-off
values, the lower of which (2.4%) was predominant
(P<0.0001), though the higher (4.1%) was also statistically
significant (P<0.01). The lower optimal cut-off level in the
present study was also located near the median SPF, and it is
noteworthy that the ratio between the lower and higher
cut-off levels was in fact approximately the same in these two
studies (4.1/2.4 vs 12/ 7.0).
Kallioniemi et al. (1988), using flow cytometry to measure
SPF, have also sought optimal cut-off levels, and like us they
found the 7% and 12% levels to be optimal. However, they
recommended the use of the lower value in diploid tumours
and of the higher in non-diploid tumours.
Searching for optimal cut-off levels in patients with node-
negative breast cancer, Clark et al. (1989) found a single
optimal cut-off level in the whole series (6.7%), which was
above their median cut-off level (5.2%). Separate multivariate
analysis for each of the ploidy categories showed that the
optimal SPF value had independent prognostic value only in
cases of diploid tumours. Courdi et al. (1989) have found the
median SPF value as estimated by thymidine labelling index
to be the single independent prognostic factor in patients
with node-negative disease. In present study, multivariate
analysis showed ploidy status to yield no additional prognos-
tic information when the three SPF categories were included
in the analysis and we have in a recent study reported a
similar finding in patients with node-negative disease (Sigurd-
sson et al., 1989). The optimal cut-off values for node-
negative tumours were less clear-cut with a broad plateau in
x2 values between the 7 and 13% levels, which might explain
the discrepancy in results between these studies. We recom-
mend that optimisation of SPF should first be done in the
whole series, with subsequent checks to see whether the
results can be confirmed in different subgroups of patients.
To ascertain whether there was a biological explanation of
the 7 and 12% levels, a subgroup analysis was undertaken
comparing premenopausal and post-menopausal patients and
steroid receptor positive and negative cases. Menstrual status
at the time of diagnosis did not affect the optimal cut-off
levels. Steroid receptor positive tumours manifested a plateau
in x2 values between the 5 and 12% levels, and one predom-
inant cut-off point at the 7% level. With steroid receptor
negative tumours, however, optimal cut-off levels were
obtained both at the 7 and 12% levels. As a uniform histo-
pathological review of the material has yet to be carried out
it cannot be excluded that the two optimal threshold levels
reflect differences in tumour differentiation.
To exclude a time-dependent bias in relation to the main-
tained SPF levels, the cut-off levels were studied at different
durations of follow-up, and the optimal cut-off levels
remained unaffected. Nonetheless, considering the relatively
short duration of follow-up in the present study, it cannot be
excluded that the optimal cut-off levels may be time-depen-
dent, and that they would change with longer follow-up.
As both the preservation and preparation procedures of
tumour specimens, as well as the methods of measuring SPF
may vary between laboratories, so may the optimal cut-off
levels obtained. The SPF values adopted in the present study
are crude approximates, and no correction was made for
background interference by cell debris. We could not eval-
uate the SPF in 6% of cases, all but one of these were
non-diploid tumours and most of these were excluded
because the samples had high degree of background debris or
a small non-diploid population: thus the proportion of
tumours not evaluated is another variable which may differ
between laboratories. As it cannot be excluded that the non-
linear survival pattern found in the present investigation may
be related to some of the factors mentioned above it needs to
be validated independently.
In particular, diploid tumour cells are mixed to some
extent with normal cells and cell debris in the DNA histo-
gram, and hence the SPF may be either falsely low or high in
diploid tumours, as compared with non-diploid tumours, as
has in fact been demonstrated by others in comparisons of
SPF measurements with labelling index and flow cytometry
results (Meyer & Coplin, 1988). Falsely low SPF values in
diploid tumours might also explain the parabolic shape of the
survival curve - indeed it was found that the non-linear790 H. SIGURDSSON et al.
(parabolic) shape was to some extent restricted to diploid
tumours (P = 0.07). We are currently developing methods of
measuring the SPF with greater precision, using statistical
methods to adjust for background debris (Baldetorp et al.,
1989). Also of particular interest are tumours with low SPF
values and these should be analysed more thoroughly - we
will be using tumour imprints and image (static) cytometry to
investigate to what extent tumour cells are mixed with nor-
mal cells, and ifpossible to estimate the corrected SPF values
of such tumours.
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